| Continous Treatment with Ibrutinib in 100 Untreated Patients with TP53 Disrupted Chronic Lymphocytic Leukemia. A Real-Life Campus CLL Study A Visentin, FR Mauro, F Cibien, C Vitale, G Reda, A Fresa, S Ciolli, ... American Journal of Hematology 97 (3), E95-E99, 2022 | 23 | 2022 |
| Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib? A Tedeschi, AM Frustaci, FR Mauro, A Chiarenza, M Coscia, S Ciolli, ... Blood Advances 5 (24), 5490-5500, 2021 | 18 | 2021 |
| Autoimmune hemolytic anemia in chronic lymphocytic leukemia: a comprehensive review F Autore, R Pasquale, I Innocenti, A Fresa, F Sora’, L Laurenti Cancers 13 (22), 5804, 2021 | 17 | 2021 |
| Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti‐CD19 CAR‐T cells E Galli, F Sorà, S Hohaus, A Fresa, I Pansini, F Autore, E Metafuni, ... British Journal of Haematology 201 (1), 86-94, 2023 | 9 | 2023 |
| Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: a real-life CLL campus study A Visentin, FR Mauro, G Catania, A Fresa, C Vitale, A Sanna, V Mattiello, ... Frontiers in Oncology 12, 1033413, 2022 | 9 | 2022 |
| Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL D Antic, N Milic, T Chatzikonstantinou, L Scarfò, V Otasevic, N Rajovic, ... Journal of hematology & oncology 15 (1), 116, 2022 | 7 | 2022 |
| Treatment options for elderly/unfit patients with chronic lymphocytic leukemia in the era of targeted drugs: a comprehensive review A Fresa, F Autore, E Galli, A Tomasso, L Stirparo, I Innocenti, L Laurenti Journal of Clinical Medicine 10 (21), 5104, 2021 | 7 | 2021 |
| Front-line therapy for elderly chronic lymphocytic leukemia patients: bendamustine plus rituximab or chlorambucil plus rituximab? Real-life retrospective multicenter study in … F Autore, I Innocenti, F Corrente, MI Del Principe, S Rosati, P Falcucci, ... Frontiers in Oncology 10, 848, 2020 | 7 | 2020 |
| Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY T Chatzikonstantinou, L Scarfò, G Karakatsoulis, E Minga, D Chamou, ... EClinicalMedicine 65, 2023 | 5 | 2023 |
| Subcutaneous immunoglobulins in chronic lymphocytic leukemia with secondary antibody deficiency. A monocentric experience during Covid‐19 pandemics I Innocenti, A Tomasso, G Benintende, F Autore, A Fresa, F Vuono, ... Hematological Oncology 40 (3), 469-474, 2022 | 5 | 2022 |
| Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma E Galli, F Sorà, S Hohaus, S Bellesi, F Autore, E Metafuni, I Innocenti, ... Bone Marrow Transplantation 57 (5), 837-839, 2022 | 4 | 2022 |
| Non‐overt disseminated intravascular coagulopathy associated with the first obinutuzumab administration in patients with chronic lymphocytic leukemia A Fresa, F Autore, I Innocenti, A Piciocchi, A Tomasso, F Morelli, F Sorà, ... Hematological Oncology 39 (3), 423-427, 2021 | 4 | 2021 |
| Do age, fitness and concomitant medications influence management and outcomes of CLL patients treated with ibrutinib? A Tedeschi, AM Frustaci, FR Mauro, A Chiarenza, M Coscia, S Ciolli, ... Blood 136, 54-55, 2020 | 4 | 2020 |
| Role of age, fitness and concomitant medications in CLL patients treated with venetoclax AM Frustaci, A Biagi, A Chiarenza, M Coscia, S Ciolli, L Laurenti, ... Blood 136, 25-26, 2020 | 4 | 2020 |
| Hematopoiesis and immune reconstitution after CD19 directed chimeric antigen receptor T‐cells (CAR‐T): A comprehensive review on incidence, risk factors and current management E Galli, A Fresa, S Bellesi, E Metafuni, E Maiolo, I Pansini, F Frioni, ... European Journal of Haematology 112 (2), 184-196, 2024 | 3 | 2024 |
| Role of microRNAs in Chronic Lymphocytic Leukemia F Autore, A Ramassone, L Stirparo, S Pagotto, A Fresa, I Innocenti, ... International Journal of Molecular Sciences 24 (15), 12471, 2023 | 3 | 2023 |
| Measurable residual disease in chronic lymphocytic leukemia G Benintende, F Pozzo, I Innocenti, F Autore, A Fresa, G D’Arena, V Gattei, ... Frontiers in Oncology 13, 1112616, 2023 | 3 | 2023 |
| VEGF and IL-6 correlation in POEMS: a potential upcoming marker of active disease and early autologous BMT response A Tomasso, I Innocenti, F Autore, A Fresa, G Benintende, F Vuono, ... Mediterranean Journal of Hematology and Infectious Diseases 14 (1), 2022 | 3 | 2022 |
| Purging with chlorambucil to prevent infusion‐related reaction before obinutuzumab administration: A monocentric pilot experience F Autore, A Fresa, I Innocenti, A Tomasso, F Morelli, A Corbingi, F Sorà, ... Hematological Oncology 37 (5), 641-643, 2019 | 3 | 2019 |
| Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study F Autore, I Innocenti, G Reda, A Visentin, C Vitale, A Piciocchi, A Fresa, ... Hematological Oncology 41 (5), 877-883, 2023 | 2 | 2023 |
